cervical cancer
Conditions
Interventions
experimental group:Cisplatin 40 mg/m2 Iv Day 1, qw for 5 weeks
Bevacizumab 10 mg/kg a Day 1, q2w, a total of 3 courses
Radiotherapy: Pelvic radiotherapy 45Gy, 25 times, 5 times/week
After loading treatment 40Gy, 1-2 LDR or 30Gy5 HDR
Sponsors
Fuyang City Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients must meet all of the following criteria to be enrolled: 1) Age = 18 years old, less than or equal to 75 years old, gender unlimited; 2) Confirmed cervical cancer by histopathological examination; 3) FIGO stages of 2018 were IB3, IIA2-IVA; 4) No previous surgery, radiotherapy, systemic therapy, immunotherapy; 5) No distant organ metastasis; 6) Have at least one measurable lesion (compliant with RECISIT version 1.1); 7) Expected survival time =12 weeks; 8) ECOG physical condition 0-2 points; 9) The subjects' major organ functions were normal: hemoglobin =100 g/L, WBC=4× 109 /L, platelets =100× 109 /L, ALT and AST< 1.5 times the upper limit of normal (ULN), total bilirubin <1.5×ULN, serum creatinine <1.5×ULN. 10) Patients or family members can understand the study protocol and are willing to participate in the study, and sign a written informed consent; 11) Patients whom the researchers believe could benefit.
Exclusion criteria
Exclusion criteria: Patients were excluded if they met any of the following criteria: 1) Previous hysterectomy 2) People who are known to be allergic to any component of treatment regimen drugs and excipients; 3) Endovascular brachytherapy or interstitial brachytherapy is not possible due to anatomy, tumor shape, or contraindications 4) Uncontrolled hypertension, systolic blood pressure > 150mmHg or diastolic blood pressure > 90 mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy and active bleeding, pulmonary hemorrhage, hemoptysis or bloody ascites; 5) Patients with a history of grade 4 venous embolism (including pulmonary embolism); 6) Severe uncontrolled recurrent infections include abdominal infections, or other serious uncontrolled concomitant diseases (such as uncontrolled diabetes, cardiovascular and cerebrovascular diseases, severe gastrointestinal diseases, etc.); 7) Human immunodeficiency virus (HIV, HIV 1/2 antibody) positive; 8) Known history of psychotropic substance abuse or drug use; 9) Pregnant or lactating patients; 10) Present or present with other malignancies within 5 years, except cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (cancer in situ), and T1 (tumor infiltrating basal membrane); 11) The researcher decides that it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Remission;Adverse Events; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression free survival;objective response rate;Disease control rate;2-year progression-free survival;Overall survival at 2 years; | — |
Countries
China
Contacts
Public ContactGuangming Wang
Anhui Fuyang city Cancer Hospital
Outcome results
None listed